FLT3 and congenital rubella syndrome: Comprehensive serum proteomics analysis after CD19-targeted CAR-T therapy indicates that FMS-like tyrosine kinase 3 (FLT3) and mast cell immunoglobulin-like receptor 1 (MILR1) are pre-infusion predictive biomarkers for severe CRS (124).